Thrombosis in Patients with Myeloma Treated in the Myeloma IX and Myeloma XI Phase III Randomized Controlled Trials.

Newly diagnosed multiple myeloma (NDMM) patients treated with immunomodulatory drugs (IMiDs) are at high venous thrombosis (VTE) risk, but data are lacking from large prospective cohorts. We present thrombosis outcome data from Myeloma IX (n=1936) and Myeloma XI (n=4358), phase III randomized controlled trials for NDMM, treating transplant-eligible and ineligible patients before and after publication of thrombosis prevention guidelines. In Myeloma IX, compared to CTD (cyclophosphamide, thalidomide and dexamethasone), transplant-eligible patients randomized to CVAD induction (cyclophosphamide, vincristine, doxorubicin and dexamethasone) had higher VTE risk (22.5%(n=121/538) vs 16.1%(n=89/554), aHR:1.46,95%CI:1.11-1.93). For transplant-ineligible patients, compared to MP (melphalan and prednisolone), patients randomized to CTDa (attenuated CTD) induction had higher VTE risk (16.0%(n=68/425) vs 4.1%(n=17/419), aHR:4.25,95%CI:2.50-7.20). In Myeloma XI, there was no difference in VTE or arterial thrombosis risk between transplant-eligible pathways, CRD (cyclophosphamide, lenalidomide and dexamethasone) and CTD (VTE:12.2%(n=124/1014) vs 13.2%(n=133/1008), aHR:0.92,95%CI:0.72-1.18; arterial events:1.2%(n=12/1014) vs 1.5%(n=15/1008), aHR:0.80,95%CI:0.37-1.70). For transplant-ineligible patients, there was no difference in VTEs between CRDa (attenuated CRD) and CTDa (10.4%(n=95/916) vs 10.7%(n=97/910), aHR:0.97, 95%CI:0.73-1.29). However, arterial risk was higher with CRDa than CTDa (3.1%(n=28/916) vs 1.6%(n=15/910), aHR:1.91,95%CI:1.02-3.57). Thrombotic events occurred almost entirely within 6m of treatment initiation. Thrombosis was not associated with inferior progression-free or overall survival (OS), apart from inferior OS for patients with arterial events (aHR:1.53, 95%CI:1.12-2.08) in Myeloma XI. The Myeloma XI trial protocol incorporated IMWG thrombosis prevention recommendations and compared to Myeloma IX, more patients were on thromboprophylaxis (80.5% vs 22.3%) with lower VTE rates for identical regimens (CTD:13.2% vs 16.1%, CTDa:10.7% vs 16.0%). However, thrombosis remained frequent in spite of IMWG-guided thromboprophylaxis, suggesting new approaches are needed.

[1]  X. Leleu,et al.  Predicting the risk of venous thromboembolism in newly diagnosed myeloma with immunomodulatory drugs: External validation of the IMPEDE VTE score , 2020, American journal of hematology.

[2]  B. Gage,et al.  Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score , 2019, American journal of hematology.

[3]  G. Morgan,et al.  Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial , 2019, The Lancet. Haematology.

[4]  B. Gage,et al.  Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  R. Benjamin,et al.  What are the difficulties in conducting randomised controlled trials of thromboprophylaxis in myeloma patients and how can we address these? Lessons from apixaban versus LMWH or aspirin as thromboprophylaxis in newly diagnosed multiple myeloma (TiMM) feasibility clinical trial , 2019, Journal of Thrombosis and Thrombolysis.

[6]  B. Pégourié,et al.  Apixaban for the prevention of thromboembolism in immunomodulatory‐treated myeloma patients: Myelaxat, a phase 2 pilot study , 2019, American journal of hematology.

[7]  A. Mathur,et al.  Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide‐ and lenalidomide‐containing regimens , 2019, British journal of haematology.

[8]  G. Morgan,et al.  Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial , 2019, The Lancet. Oncology.

[9]  Ang Li,et al.  The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma , 2018, Annals of Hematology.

[10]  C. Bradbury,et al.  Venous thromboembolism in multiple myeloma – choice of prophylaxis, role of direct oral anticoagulants and special considerations , 2018, British journal of haematology.

[11]  B. Gage,et al.  Association of venous thromboembolism with increased mortality in patients with multiple myeloma. , 2018 .

[12]  B. Gage,et al.  Aspirin May be Inadequate Thromboprophylaxis in Multiple Myeloma , 2017 .

[13]  P. Bennett,et al.  “Post‐thrombotic panic syndrome”: A thematic analysis of the experience of venous thromboembolism , 2017, British journal of health psychology.

[14]  M. Mateos,et al.  Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review. , 2016, Thrombosis research.

[15]  T. Kebdani,et al.  Venous thromboembolism in cancer patients: an underestimated major health problem , 2015, World Journal of Surgical Oncology.

[16]  C. Martinez,et al.  Epidemiology of first and recurrent venous thromboembolism: A population-based cohort study in patients without active cancer , 2014, Thrombosis and Haemostasis.

[17]  G. Morgan,et al.  Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment , 2013, Clinical Cancer Research.

[18]  O. Decaux,et al.  MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs , 2013, Thrombosis and Haemostasis.

[19]  R. Pfeiffer,et al.  Thrombosis is associated with inferior survival in multiple myeloma , 2012, Haematologica.

[20]  G. Morgan,et al.  Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results , 2012, Haematologica.

[21]  M. Boccadoro,et al.  Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. , 2012, Blood.

[22]  G. Morgan,et al.  The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. , 2012, Blood.

[23]  G. Morgan,et al.  Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. , 2011, Blood.

[24]  G. Morgan,et al.  Guidelines for the diagnosis and management of multiple myeloma 2011 , 2011, British journal of haematology.

[25]  G. Gal,et al.  Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta‐analysis , 2011, Journal of thrombosis and haemostasis : JTH.

[26]  M. Boccadoro,et al.  Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  U. Mellqvist,et al.  Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. , 2009, Blood.

[28]  A. Falanga,et al.  Venous thromboembolism in the hematologic malignancies. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  C. Eby.  Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias , 2009, British journal of haematology.

[30]  U. Mellqvist,et al.  Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. , 2008, Blood.

[31]  B. Barlogie,et al.  Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma , 2008, Leukemia.

[32]  R. Foà,et al.  Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  A. Khorana,et al.  Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy , 2007, Journal of thrombosis and haemostasis : JTH.

[34]  T. Choueiri,et al.  Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  John Crowley,et al.  Thalidomide and hematopoietic-cell transplantation for multiple myeloma. , 2006, The New England journal of medicine.

[36]  Rafael Fonseca,et al.  Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Robert A Kyle,et al.  Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. , 2005, Blood.

[38]  Liang Li,et al.  The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. , 2005, Mayo Clinic proceedings.

[39]  B. Barlogie,et al.  Total therapy with tandem transplants for newly diagnosed multiple myeloma. , 1999, Blood.